- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00703378
Target Dosing of Docetaxel Through Pharmacokinetic/Pharmacodynamic Optimisation of the First Chemotherapeutic Cycle
Primary Objective
1. To develop a pharmacokinetic-pharmacodynamic (PD) model for optimisation of docetaxel dosing
Secondary Objectives
- To establish an exposure-toxicity (neutropenia) relationship for docetaxel
- To determine the exposure breakpoint for docetaxel toxicity based on a neutropenia PD model
- To identify demographic, pathophysiological and/or phenotypic covariates predicting docetaxel clearance
- To prospectively validate this PK-PD model for optimisation of docetaxel dosage and determination PK variability and toxicity
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Rationale
Poor tolerance of standard docetaxel dosage regimens used as a single agent in Asians has been clearly demonstrated by our group in 2 separate studies. Neutropenia emerged as the most prominent manifestation of chemotherapy toxicity [12, 20]. While this has been attributed to the lower docetaxel CL derived in our Asian patients, an optimal dosage regimen taking into account the extensive genetic polymorphisms associated with CYP3A4 has yet to be established. The use of ketoconazole as a potent CYP3A4 modulator to reduce pharmacokinetic variability of docetaxel did show >2-fold reduction in docetaxel dosage, but inter-individual variability in CL was not significantly reduced. There was also poor correlation of docetaxel CL to midazolam phenotyping of CYP3A4 with the addition of ketoconazole to the regimen [23]. Since the use of an additional modulator failed to achieve the desired reduction in pharmacokinetic variability, the idea of using low-dose docetaxel to predict its own pharmacokinetic parameters appeared feasible, safe and an appealing approach.
The more acute toxicities of docetaxel, such as neutropenia, stomatitis, neurological toxicities and fluid retention are more frequently associated with the 3 weekly than weekly dosing schedule. This study is designed so that the less toxic weekly schedule is used for PK/PD correlation. This information would be utilized to derive an optimal dosage for the 3 weekly regimen that follows since cumulative myelosuppression was not observed with previous weekly docetaxel for metastatic breast cancer [31].
Currently patients with impaired liver function manifested by elevated baseline ALT/AST more than 1.5 more than the institutional limits of normal are not treated with the recommended dose of docetaxel because of impaired clearance of docetaxel. Theoretically, these patients may benefit from docetaxel treatment, but the dose will need to be individualized based on hepatic drug clearance to avoid toxicity. To determine the clinical usefulness of our strategy of predicting docetaxel clearance and individualised dosing based on clearance and a PD model, patients with a certain extent of liver dysfunction will be included into the study. They will be divided into 3 groups according to the level of AST/ALT and SAP, total bilirubin, and initial weekly doses as well as q3weekly doses will be lower than the recommended doses for patients with normal liver function. Previous investigators have reported the feasibility of using the erythromycin breath test as an in vivo probe for CYP3A activity and docetaxel clearance in patients with liver dysfunction (Baker SD et al Evaluation of CYP3A activity as a predictor covariate for docetaxel clearance Proceedings of ASCO 2004; 128: 2006abs).
2.4 Hypothesis
The hypothesis for this study is that PK/PD guided dosing of docetaxel will reduce the variability in docetaxel PK while achieving the maximum exposure desired within acceptable limits of toxicity. At this juncture, this is a novel approach in oncology to fully exploit the potential of using low-dose docetaxel as its own probe drug to individualise and optimise dosage for subsequent chemotherapy treatment without having to use other agents to modulate or predict drug metabolism and clearance.
Type d'étude
Inscription (Réel)
Phase
- Phase 2
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
-
Singapore, Singapour
- National University Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Patients must have histologically confirmed malignancy that is metastatic or unresectable and for which docetaxel is indicated.
- Patients must have measurable or evaluable disease.
- With the exception of alopecia, fatigue, nausea and asthenia, patients must have resolution of all acute toxic effects of any prior surgery' radiotherapy or chemotherapy to National Cancer Institute (NCI) Common Toxicity Criteria version 3.0 (see Appendix A) grade < 1.
- Patients must have ECOG performance status < 2 (Karnofsky >60%, see Appendix B).
- Patients must have a life expectancy of greater than 3 months.
Patients must have normal renal and marrow function as defined below:
- leukocytes ≥3,000/μl
- absolute neutrophil count ≥1,500/μl
- platelets ≥100,000/μl
- haemoglobin ≥7g/dL
- creatinine ≤1.5 X institutional upper limit of normal
- Patients with abnormal liver function tests (AST/ALT ≤ 10 x institutional upper limits of normal; SAP < 5x ULN; total bilirubin ≤ 1.5x ULN) will be eligible for enrolment.
- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation. Females with childbearing potential must have a negative serum pregnancy test within 7days prior to study enrollment. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
- Patients may not be receiving any other investigational agents.
- Patients who have rapidly progressive intracranial or spinal metastatic disease (including patients who require corticosteroid for CNS disease).
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to docetaxel or other agents used in study.
- Patients who have prior medications known to be metabolized by or induce/inhibit CYP3A4 within 1 week (see appendix C).
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Pregnant women are excluded from this study because docetaxel is embryotoxic/fetotoxic with the potential for abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with docetaxel, breastfeeding should be discontinued if the mother is treated with docetaxel. These potential risks may also apply to other agents used in this study.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Group 1
Group 1: normal liver function
|
Phase 1 Cycle 1 and 2 Patients in group 1 receive 40mg/m2/week of docetaxel in a 1-hour infusion.
Patients in group 2 receive 30mg/m2/week of docetaxel in a 1-hour infusion.
Patients in group 3 receive 20mg/m2/week of docetaxel in a 1-hour infusion.
Autres noms:
|
Expérimental: Group 2
Group 2: AST and/or ALT up to 1-5 x upper limit of normal; SAP 1- 5x upper limit of normal, total bilirubin within normal limits
|
Phase 1 Cycle 1 and 2 Patients in group 1 receive 40mg/m2/week of docetaxel in a 1-hour infusion.
Patients in group 2 receive 30mg/m2/week of docetaxel in a 1-hour infusion.
Patients in group 3 receive 20mg/m2/week of docetaxel in a 1-hour infusion.
Autres noms:
|
Expérimental: Group 3
Group 3: Any SAP and AST/ALT >5-10 x upper limit of normal and/or total bilirubin 1-1.5 x upper limit of normal
|
Phase 1 Cycle 1 and 2 Patients in group 1 receive 40mg/m2/week of docetaxel in a 1-hour infusion.
Patients in group 2 receive 30mg/m2/week of docetaxel in a 1-hour infusion.
Patients in group 3 receive 20mg/m2/week of docetaxel in a 1-hour infusion.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
change in neutrophil counts and docetaxel AUC
Délai: 3 weeks
|
. Based on maximal acceptable toxicity, expressed as the reduction in neutrophil count, the corresponding breakpoint for AUC will be identified as the PK target.
Both linear regression and nonlinear mixed effects modeling will be employed to establish a relationship between docetaxel CL and demographic, phenotypic and pathophysiological factors.
|
3 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Pharmacokinetic sampling of docetaxel serum concentrations
Délai: 7 weeks
|
Pharmacokinetic sampling of docetaxel serum concentrations will be carried out around the first course of docetaxel administration of both cycles 1a and 1b of the chemotherapy regimen.
The time points elected for docetaxel sampling are: 0h (baseline), 15mins, 1.5h, 3h, 4h, 6h and 24h.
|
7 weeks
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Boon Cher Goh, MBBS, MRCP, National University Hospital, Singapore
Publications et liens utiles
Publications générales
- Goh BC, Lee SC, Wang LZ, Fan L, Guo JY, Lamba J, Schuetz E, Lim R, Lim HL, Ong AB, Lee HS. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol. 2002 Sep 1;20(17):3683-90. doi: 10.1200/JCO.2002.01.025.
- Goh BC, Lehnert M, Lim HL, Ng AW, Chan CC, Kong HL, Lee SC, Wee J, Chua ET, Wong JE. Phase II trial of docetaxel in Asian patients with inoperable stage III non-small cell lung cancer. Acta Oncol. 2000;39(2):225-9. doi: 10.1080/028418600430824.
- Syn NL, Wang L, Wong AL, Soe MY, Chuah B, Chan D, Tan SH, Soo RA, Lee SC, Goh BC, Yong WP. Dose modifications in Asian cancer patients with hepatic dysfunction receiving weekly docetaxel: A prospective pharmacokinetic and safety study. Cancer Sci. 2016 Feb;107(2):173-80. doi: 10.1111/cas.12856. Epub 2016 Feb 8.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- PK01/06/05
- 2005/00082 (Autre identifiant: NHG Domain Specific Review Boards)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Tumeurs solides
-
AstraZenecaRecrutementAdv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian CancerEspagne, États-Unis, Belgique, Royaume-Uni, France, Hongrie, Canada, Corée, République de, Australie
-
Shattuck Labs, Inc.Actif, ne recrute pasMélanome | Carcinome à cellules rénales | Lymphome de Hodgkin | Adénocarcinome gastrique | Cancer du poumon non à petites cellules | Carcinome épidermoïde de la tête et du cou | Lymphome diffus à grandes cellules B | Carcinome urothélial | Adénocarcinome de la jonction gastro-oesophagienne | Carcinome... et d'autres conditionsÉtats-Unis, Canada, Belgique, Espagne
Essais cliniques sur Docetaxel (Taxotere®)
-
Assiut UniversityInconnueCarcinome épidermoïde de la tête et du cou
-
Oshadi Drug AdministrationInconnueCarcinome pulmonaire non à petites cellulesIsraël
-
Fudan UniversityPas encore de recrutementCancer du poumon non à petites cellules avancé
-
Wake Forest University Health SciencesAstellas Pharma Inc; Medivation, Inc.Actif, ne recrute pasCancer de la prostate | Adénocarcinome de la prostateÉtats-Unis
-
University Hospital, BonnSanofiInconnue
-
Zhao ChongZhejiang Cancer Hospital; Wuhan University; Fudan University; Fujian Cancer Hospital et autres collaborateursComplétéCarcinome du nasopharynx | MalnutritionChine
-
Tianjin Medical University Cancer Institute and...Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Pas encore de recrutementCancer du poumon non à petites cellules localement avancé résécableChine
-
Samsung Medical CenterSanofiComplétéCarcinome pulmonaire non à petites cellulesCorée, République de
-
Nicklaus Children's Hospital f/k/a Miami Children...Actif, ne recrute pasOstéosarcome métastatique | Sarcome d'Ewing métastatiqueÉtats-Unis
-
Dong-A ST Co., Ltd.ComplétéDyspepsie fonctionnelleCorée, République de